Ariana Neely

MDS-1378: Genetic Ancestry Shapes Mutation Prevalence in MDS Patients Beyond Self-Reported Race

Kanayo Nwankwo, Chidiebube Ugwu, Chika A. Nmaju, Angimar Uriepero Palma et autres

us, gb (code pays fourni par la source)

POSTER: MDS-1378: Genetic Ancestry Shapes Mutation Prevalence in MDS Patients Beyond Self-Reported Race

Kanayo Nwankwo, Chidiebube Ugwu, Chika A. Nmaju, Angimar Uriepero Palma et autres

us, gb (code pays fourni par la source)

A real-world analysis on the management of post-mastectomy lymphedema in breast cancer patients: The therapeutic promise of glucagon-like peptide-1 receptor agonist.

Muluken Megiso, Dawit Yesho, Chidebube Zeleke Ugwu, Ariana Neely et autres

e12695 Background: Post mastectomy lymphedema syndrome (PMLS) is an established complication of mastectomy, and the risk is further exacerbated by obesity and insulin resistance. Glucagon-like-peptide 1 receptor agonists (GLP-1RAs) are known to reduce body mass index (BMI) and inflammation while improving insulin …

us (code pays fourni par la source)

Tu1549 IMPACT OF GLP-1 RECEPTOR AGONIST THERAPY ON CLINICAL OUTCOMES IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND OBESITY: A MULTICENTER REAL-WORLD ANALYSIS

Karecia Byfield, Tinsae Anebo, Kevin Robinson, Fnu Deepali et autres

Tu2068 A REAL-WORLD ANALYSIS ON MITIGATING ALL-CAUSE MORTALITY AND GASTROINTESTINAL COMPLICATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS WITH DIABETES: THE THERAPEUTIC ROLE OF GLP-1 AGONIST

Akil Olliverrie, Ariana Neely, Damion Persad, Colton Jones

Tu2068 A REAL-WORLD ANALYSIS ON MITIGATING ALL-CAUSE MORTALITY AND GASTROINTESTINAL COMPLICATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS WITH DIABETES: THE THERAPEUTIC ROLE OF GLP-1 AGONIST

Akil Olliverrie, Ariana Neely, Damion Persad, Colton Jones

Tu1549 IMPACT OF GLP-1 RECEPTOR AGONIST THERAPY ON CLINICAL OUTCOMES IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND OBESITY: A MULTICENTER REAL-WORLD ANALYSIS

Karecia Byfield, Tinsae Anebo, Kevin Robinson, Fnu Deepali et autres

Abstract 3994: Differences in the mutational landscape across race and sex highlight distinct TP53-associated risk in multiple myeloma

Chidiebube Ugwu, Nneoma Ubah, Muluken Megiso, Angimar Uriepero Palma et autres

Abstract Background: Complex health disparities involving race, sex, and genomics have been described in multiple myeloma (MM) (Tebuka E et al. Blood Gl. Hem. 2025). Large genomic studies have highlighted the impact of the mutational landscape (Maura F et al. JCO 2024; …

us, de (code pays fourni par la source)

GLP-1 receptor agonist vs aspirin for primary prevention of colorectal cancer: Evidence from a real-world head-to-head comparison.

Colton Jones, Elvis Obomanu, Ariana Neely, Karecia Byfield et autres

18 Background: Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality. While aspirin has long been studied and utilized for chemoprevention, emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may also confer anticancer benefits by exerting anti-inflammatory and …

us (code pays fourni par la source)

Real-world analysis on the impact of GLP-1 receptor agonists on survival and metastatic risk in colorectal cancer.

Colton Jones, Ariana Neely, Elvis Obomanu, Oscar Hinojosa et autres

62 Background: GLP-1 receptor agonists (GLP-1RAs), commonly prescribed for type 2 diabetes (T2DM) and obesity, have demonstrated anti-proliferative effects in colorectal cancer (CRC) cell lines by inhibiting the PI3K/Akt/mTOR pathway. However, clinical data on the impact of GLP-1RAs on CRC outcomes remains …

us (code pays fourni par la source)